Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LVGN3616 + LVGN6051 + LVGN7409 + paclitaxel
- Development stage
- Unknown
- Lead developer
- Lijin Biomedical Technology
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is an investigational combination therapy consisting of three novel monoclonal antibodies—LVGN3616 (pradusinstobart), a PD-1 inhibitor; LVGN6051 (exlinkibart), and LVGN7409 (dalnicastobart)—administered together with paclitaxel (a well-established chemotherapeutic agent). The regimen is being evaluated in phase 1 clinical trials for the treatment of various metastatic solid tumors including gastric cancer, liver cancer, and sarcoma. The monoclonal antibodies are designed to enhance antitumor immune responses by targeting immune checkpoint pathways and other immunomodulatory targets. Paclitaxel acts as a mitotic inhibitor that disrupts microtubule function in dividing cells. Lvygen Biopharma supplies the investigational antibodies for these studies[3][5][7][8].
- Other names
- pradusinstobartexlinkibartdalnicastobart
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD40 (Cluster of differentiation 40 receptor)TNFRSF9 (CD137 extracellular domain)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on LVGN3616 + LVGN6051 + LVGN7409 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LVGN3616 + LVGN6051 + LVGN7409 + paclitaxel.